Trials / Completed
CompletedNCT02576002
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
Study to Estimate the Incidence and Prevalence and Treatment Patterns of Pediatric Pulmonary Hypertension in the US
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,691 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Assigned pulmonary hypertension medication | As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-10-15
- Last updated
- 2016-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02576002. Inclusion in this directory is not an endorsement.